ABBOTT LABORATORIES

ISIN: US0028241000 WKN: 002824100 Asset Class: Stock



Company Profile

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Financial	figures, Fisca	l year: from	01.01. to 31.12.

	2023		2022		2021	
Financial figures	Assets I	_iabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	22,670,000,000		25,224,000,000		24,239,000,000	
Common stock capital		24,869,000,000		24,709,000,000		24,470,000,000
Fixed assets	50,544,000,000		49,214,000,000		50,957,000,000	
Equity capital of a company		38,827,000,000		36,905,000,000		36,024,000,000
Cash and cash equivalents	6,896,000,000		9,882,000,000		9,799,000,000	
Accrued liabilities		1,964,000,000		1,784,000,000		2,738,000,000
Other assets	-		-		-	
Current liabilities		13,841,000,000		15,489,000,000		13,105,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		20,546,000,000		22,044,000,000		26,067,000,000
Different income		-		-		-
Other liabilities		2,816,000,000		2,954,000,000		3,005,000,000
Total assets	73,214,000,000	73,214,000,000	74,438,000,000	74,438,000,000	75,196,000,000	75,196,000,000

D - I				-4-	_
Bal	an	Ce	n	ote	S

	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	114,000	115,000	113,000
Equity ratio	53.34%	49.87%	48.20%
Debt-equity ratio	87.48%	100.51%	107.46%

_				
n	t	h	Δ	r

	2023	2022	2021
Tax Expense Rate	14.12%	16.53%	13.88%

ABBOTT LABORATORIES

ISIN: US0028241000 WKN: 002824100 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	40,109,000,000	43,653,000,000	43,075,000,000
Net income	5,701,000,000	6,905,000,000	7,042,000,000
EBIT	6,541,635,200	7,911,468,800	8,042,732,800
Operating income before taxes	6,664,000,000	8,306,000,000	8,211,000,000
Cash Flow	7,261,000,000	9,581,000,000	10,533,000,000
Net interest income	-313,000,000	-132,000,000	-367,000,000
Research and development expenses	2,719,000,000	2,852,000,000	2,738,000,000
Income taxes	941,000,000	1,373,000,000	1,140,000,000
Result from investments in subsidaries, associates and other	-	-	0
Revenues per employee	329,879	355,905	357,408

Board of Directors

Members of Management Board			
Robert Alpern	Member of Board of Directors		
Sally Blount	Member of Board of Directors		
Claire Babineaux-Fontenot	Member of Board of Directors		
Daniel Starks	Member of Board of Directors		
Darren McDew	Member of Board of Directors		
John Stratton	Member of Board of Directors		
Michael O'Grady	Member of Board of Directors		
Michael Roman	Member of Board of Directors		
Michelle Kumbier	Member of Board of Directors		
Nancy McKinstry	Member of Board of Directors		
Paola Gonzalez	Member of Board of Directors		
Robert B. Ford	Chairman of Managing Board		
Andrea F. Wainer	Member of Executive Committee		
Daniel Salvadori	Member of Executive Committee		
Hubert L. Allen	Member of Executive Committee		
Lisa D. Earnhardt	Member of Executive Committee		
Mary K. Moreland	Member of Executive Committee		
Robert E. Funck, Jr.	Member of Executive Committee		